Tumor-antigen-specific CD4 T cells are frequently detected in cancer patients15–17, and vaccination that boosts tumor-antigen-specific CD4 and CD8 T cells has resulted in clinical benefit including cases of complete response18–20. Here, CD8A is linked to neoplasm.